Vinblastinum [Inn-Latin]

Vinblastinum [Inn-Latin] Brand names, Vinblastinum [Inn-Latin] Analogs

Vinblastinum [Inn-Latin] Brand Names Mixture

No information avaliable

Vinblastinum [Inn-Latin] Chemical_Formula

C₄₆H₅₈N₄O₉

Vinblastinum [Inn-Latin] RX_link

http://www.rxlist.com/cgi/generic3/vinblastine.htm

Vinblastinum [Inn-Latin] fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=29

Vinblastinum [Inn-Latin] msds (material safety sheet)

Vinblastinum_[Inn-Latin] MSDS

Vinblastinum [Inn-Latin] Synthesis Reference

No information avaliable

Vinblastinum [Inn-Latin] Molecular Weight

810.974 g/mol

Vinblastinum [Inn-Latin] Melting Point

267 ^oC

Vinblastinum [Inn-Latin] H₂O Solubility

Negligible

Vinblastinum [Inn-Latin] State

Solid

Vinblastinum [Inn-Latin] LogP

5.587

Vinblastinum [Inn-Latin] Dosage Forms

Liquid; Powder for solution; Solution

Vinblastinum [Inn-Latin] Indication

For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Vinblastinum [Inn-Latin] Pharmacology

Vinblastine is a vinca alkaloid antineoplastic agent. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units: vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinblastine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

Vinblastinum [Inn-Latin] Absorption